Amrita Krishnan, M.D.

(877) 460-4673
Amrita Krishnan, M.D.
Hematologist
Clinical Expertise
  • Multiple Myeloma
  • Hematopoietic Cell Transplantation
Research Area
  • Multiple Myeloma
  • Myeloma
  • Hematology and Hematopoietic Cell Transplantation
Other Languages Spoken
French
Academic Appointments
  • Nason-Hollingsworth Chair in Multiple Myeloma
  • Executive Medical Director, Hematology, City of Hope Orange County
  • Director, Judy and Bernard Briskin Multiple Myeloma Center
  • Professor, Department of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Bone Marrow and Stem Cell Transplantation
Myeloma and Multiple Myeloma
Hematology & Hematopoietic Cell Transplantation

Equally driven as a clinician and researcher, Amrita Krishnan, M.D., was instrumental in bringing successful transplant therapy to HIV patients with lymphoma, when many believed such patients were too weak to tolerate the procedure.

“We have patients who had been told to get their affairs in order,” she says. “Years later, they are still here.”

Dr. Krishnan now directs the Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope, seeking to make gains in one of the most rapidly changing areas in cancer research.

A key member of the City of Hope team since 1996, Dr. Krishnan trained at The University of Rochester, Beth Israel Hospital, Fred Hutchinson Research Cancer Center and Dana Farber Cancer Institute. Serves as a steering committee member on the Multiple Myeloma Research Foundation and the North American representative to the International Myeloma Society, former chair of the Blood and Marrow Transplant Clinical Trials Network myeloma committee and is the Co-Chair of several of the largest myeloma transplant trials in the U.S.

Her research interests are in the development of new drugs for relapsed myeloma and understanding mechanisms of disease resistance.

Location

Education & Experience

Degrees

  • 1990, Albany Medical College, Albany, NY, M.D., Medicine
  • 1988, Union College, Schenectady, NY, B.S., Biology/Modern Languages

Fellowship

  • 1996–1997, Clinical Fellow, Bone Marrow Transplantation City of Hope
  • 1993–1996, Clinical Fellow, Hematology–oncology Beth Israel Hospital, Harvard University Boston MA
  • 1993–1996, Clinical Fellow Clinical Fellow in Medicine, Harvard Medical School Boston MA
  • 1995–1996, Research Fellow Division of Hematologic Malignancies, Principal Investigator, J. Ritz Dana Farber Cancer Institute Harvard University, Boston MA
  • 1995, Clinical Fellow, Bone Marrow Transplantation Fred Hutchinson Cancer Research Center, University of Washington Seattle WA
  • 1995, Clinical Fellow, Bone Marrow Transplantation, Solid Tumor and Lymphoma Autologous Marrow Program Dana Farber Cancer Institute and Beth Israel Hospital, Boston, MA

Residency

  • 1991–1993, Strong Memorial Hospital University of Rochester, Rochester, NY

Professional Experience

  • 2025–present, Nason-Hollingsworth Chair in Multiple Myeloma, City of Hope, Duarte, CA
  • 2022–present, Executive Medical Director, Hematology, City of Hope Orange County
  • 2021–present, Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
  • 2015–present, Director, Judy and Bernard Briskin Center for Myeloma, City of Hope, Duarte, CA
  • 2004–2018, Associate Director, Medical Education and Training, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope
  • 1997–present, Staff Physician, Department of Hematology and Hematopoietic Cell Transplantation City of Hope

Publications

  • Dona AA, Sanchez JF, Palmer JM, Synold TW, Chiuppesi F, Thomas S, Caserta E, Singer M, Tandoh T, Chowdhury A, Krishnan A, Rosenzweig M, Diamond DJ, Rosen S, Pichiorri F, Dadwal S. Leflunomide Confers Rapid Recovery from COVID-19 and is Coupled with Temporal Immunologic Changes. J Immunol Sci. 2023;7(1):9-27. doi: 10.29245/2578-3009/2023/1.1241. Epub 2023 Jan 20. PMID: 36996290; PMCID: PMC10042490.
  • D'Souza A, Brazauskas R, Stadtmauer EA, Pasquini MC, Hari P, Bashey A, Callander N, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Landau H, Brunstein C, McCarthy P, Qazilbash MH, Giralt S, Krishnan A, Flynn KE. Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. Am J Hematol. 2023 Jan;98(1):140-147. doi: 10.1002/ajh.26596. Epub 2022 May 21. PMID: 35567778; PMCID: PMC9659666.
  • Tanenbaum HC, Birmann BM, Bertrand KA, Teras LR, Krishnan AY, Pourhassan H, Goldsmith S, Cannavale K, Wang SS, Chao CR. Identifying monoclonal gammopathy of undetermined significance from electronic health records. Cancer Rep (Hoboken). 2023 Mar;6(3):e1755. doi: 10.1002/cnr2.1755. Epub ahead of print. PMID: 36464325.
  • Murtadha M, Park M, Zhu Y, Caserta E, Dona AA, Singer M, Vahed H, Tasndoh T, Gonzalez A, Ly K, Sanchez JF, Chowdhury A, Pozhitkov A, Ghoda L, Li L, Zhang B, Krishnan A, Marcucci G, Williams J, Pichiorri F. Leveraging IFNγ/CD38 regulation to unmask and target leukemia stem cells in acute myelogenous leukemia. bioRxiv [Preprint]. 2023 Mar 1:2023.02.27.530273. doi: 10.1101/2023.02.27.530273. PMID: 36909542; PMCID: PMC10002674.
  • Mohan M, Janz S, Brazauskas R, Dwinell MB, Teng BQ, Yun G, Dong J, Pasquini MC, Giralt S, Landau H, Stadtmauer E, Krishnan A, D'Souza A. Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy. Bone Marrow Transplant. 2023 May 6. doi: 10.1038/s41409-023-02004-5. Online ahead of print. PMID: 37149674
  • Krishnan A, Nooka AK, Chari A, Garfall AL, Martin TG, Nair S, Lin X, Qi K, Londhe A, Pei L, Ammann E, Kobos R, Smit J, Parekh T, Marshall A, Slavcev M, Usmani SZ.Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma. J Comp Eff Res. 2023 Jun;12(6):e220186. doi: 10.57264/cer-2022-0186. Epub 2023 Apr 28. PMID: 37114426
  • Lewinsky H, Gunes EG, David K, Radomir L, Kramer MP, Pellegrino B, Perpinial M, Chen J, He TF, Mansour AG, Teng KY, Bhattacharya S, Caserta E, Troadec E, Lee P, Feng M, Keats J, Krishnan A, Rosenzweig M, Yu J, Caligiuri MA, Cohen Y, Shevetz O, Becker-Herman S, Pichiorri F, Rosen S, Shachar I. CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma.JCI Insight. 2023 Jul 24;8(14):e173312. doi: 10.1172/jci.insight.173312.PMID: 37485873
  • Chari A, Askari E, Caers J, Costa LJ, Hilder BW, Krishnan A, Mateos MV, Minnema MC, Oriol A, Pillarisetti K, van de Donk NWCJ, Rodríguez-Otero P. Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma. Future Oncol. 2023 Jul 26. doi: 10.2217/fon-2023-0332. Online ahead of print.PMID: 37492991.
  • Sidana S, Moreau P, Garfall A, Bhutani M, Oriol A, Nooka A, Martin T, Rosiñol Dachs L, Mateos MV, Bahlis NJ, Popat R, Besemer B, Martinez-Lopez J, Krishnan A, et. al. P879: Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). HemaSphere. 2023 Aug 8;7(Suppl ):e62475d0. doi: 10.1097/01.HS9.0000970420.62475.d0. PMCID: PMC10431083.
  • Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, Chojnacka M, Cirrincione A, Durante M, Tilmont R, Barakat E, Poorebrahim M, Sinha S, McIntyre J, M Y Chan A, Wilson H, Kyman S, Krishnan A, et. al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023 Sep;29(9):2295-2306. doi: 10.1038/s41591-023-02491-5. Epub 2023 Aug 31. PMID: 37653344; PMCID: PMC10504087.
  • Miao X, Wu LS, Lin SXW, Xu Y, Chen Y, Iwaki Y, Kobos R, Stephenson T, Kemmerer K, Uhlar CM, Banerjee A, Goldberg JD, Trancucci D, Apte A, Verona R, Pei L, Desai R, Hickey K, Su Y, Ouellet D, Samtani MN, Guo Y, Garfall AL, Krishnan A, Usmani SZ, Zhou H, Girgis S. Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1. Target Oncol. 2023 Sep;18(5):667-684. doi: 10.1007/s11523-023-00989-z. Epub 2023 Sep 15. PMID: 37713090; PMCID: PMC10518021.
  • Liu, L. and Krishnan, A. (2023) “Talquetamab in multiple myeloma”, Haematologica. Early view Oct 19, 2023 doi: 10.3324/haematol.2023.283931.
  • Malek E, Kort J, Metheny L, Fu P, Hari P, Li G, Efebera Y, Callander N, Qazilbash M, Giralt S, Krishnan A, et. al. Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial. Res Sq [Preprint]. 2023 Sep 21:rs.3.rs-3318127. doi: 10.21203/rs.3.rs-3318127/v1. Update in: Transplant Cell Ther. 2024 Jan 18;: PMID: 37790413; PMCID: PMC10543370.
  • Rhee JW, Pillai R, He T, Bosworth A, Chen S, Atencio L, Oganesyan A, Peng K, Guzman T, Lukas K, Sigala B, Iukuridze A, Lindenfeld L, Jamal F, Natarajan P, Goldsmith S, Krishnan A. et. Al. Clonal Hematopoiesis and Cardiovascular Disease in Patients With Multiple Myeloma Undergoing Hematopoietic Cell Transplant. JAMA Cardiol. 2024 Jan 1;9(1):16-24. doi: 10.1001/jamacardio.2023.4105. PMID: 37938837; PMCID: PMC10633387.
  • Stevens MM, Kimmerling RJ, Olcum S, Vacha M, LaBella R, Minnah A, Katsis K, Fujii J, Shaheen Z, Sundaresan S, Criscitiello J, Niesvizky R, Raje N, Branagan A, Krishnan A, et al. Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies. JCO Precis Oncol. 2024 Jan;8:e2300349. doi: 10.1200/PO.23.00349. PMID: 38237098; PMCID: PMC10805426.

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
5.0
Recommend this provider office
5.0
Show respect for what you say
4.9
Provider explain in way you understand
4.9
Provider listen carefully to you
4.9
Know important info medical history
4.9
Spend enough time with you
4.9
Rate provider 0-10
03/12/26
I have brought 7 patients to city of Hope. And another one soon. [...] - Verified patient
01/20/26
Great team working for my health - Verified patient
01/20/26
City of Hope is the best - Verified patient
11/28/25
Doctor Krishnan is brilliant. I have recommended her to two people and she is saving their lives too! Amazing doctor and wonderful keeping us multiple myeloma people healthy, living our best lives! - Verified patient
11/23/25
Dr Krishnan demonstrates the greatest care and compassion. She is the best! - Verified patient